Posted by Michael Wonder on 07 Feb 2023
Forxiga approved in the EU for the treatment of symptomatic chronic heart failure
7 February 2023 - First and only heart failure therapy with proven mortality benefit across the full ejection fraction range
Forxiga (dapagliflozin) has been approved in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the full spectrum of left ventricular ejection fraction, including heart failure with mildly reduced and preserved ejection fraction.
